Product Images Pradaxa

This is a description of a medication called Dabigatran. It comes in the form of a blue/white capsule with the label R150. The medication contains etexilate 150mg and should be stored at room temperature between 20°-25°C (68°-77°F). The medication is comparable to Pradaxa 150mg Capsule. A package contains 30 capsules and has an expiration date of MM/YY. The National Drug Code (NDC) for this medication is 6362982421 08242301523487. All drugs should be kept out of reach of children.*

The text provides clinical trial data on Major bleeding events recorded on treatment + 2 days using PRADAXA 150 in comparison to Warfarin. The safety set included 18040 patients with different characteristics such as VKA use, age, gender, weight, history of stroke/TIA diabetic status, CHADS score, CICL, region, and ASA use at baseline. The table shows the number and percentage of patients experiencing bleeding events in different subgroups of patients. The data also includes hazard ratios for PRADAXA 150 versus Warfarin.*

This appears to be a chart that shows the time course of aPTT (activated partial thromboplastin time) in seconds for patients who are receiving different doses of PRADAXA depending on their creatinine clearance rate. The chart shows that the recommended dose is 150 mg twice daily for patients whose creatinine clearance rate is over 30 mL/min, and 75 mg twice daily for patients whose creatinine clearance rate is less than or equal to 30 mL/min. The chart shows a reduction in aPTT over time for both dosing regimens.*

This appears to be a table or data chart showing the results of testing the effects of various drugs on PK (pharmacokinetics) fold change. The drugs listed are P-gp inhibitors and gp inducers, with different dosages and administration frequencies (SD = single dose, qd = once daily, bid = twice daily), and the table includes time difference and confidence interval values. The table also appears to show the relative change in PK compared to a reference.*

This appears to be a table of drugs with their corresponding dosages and administration frequency. The table also includes time difference, PK fold change, and 90% CT values, which likely refer to pharmacokinetic parameters of the drugs.*

This text describes a randomized study comparing the efficacy of Pradaxa 150 to warfarin in preventing stroke and systemic embolism (SEE) in 18,113 patients with atrial fibrillation over a specific period of time. The patients were divided into subgroups based on their age, gender, weight, history of stroke or transient ischemic attack (TIA), diabetes, CHADS2 score, location, and use of aspirin. The text provides statistical data regarding these subgroups, including the total number of patients, hazard ratios (HR), and confidence intervals (CI), and a comparison of Pradaxa 150 versus warfarin. The third page also contains a table that cannot be reasonably interpreted.*